1
|
Olmez O, Bilici A, Er Ö, Sevinç A, Akman T, Uslu R, Mandel N, Yalçın Ş, Teomete M, Görümlü G, Demir A, Namal E, Alıcı S, Selçukbiricik F, Bavbek S, Paksoy F, Başaran G, Özer L, Şener N, Harputluoğlu H. 2008P The effect of the use of complex molecular profiling in advanced solid organ tumours on clinical decision: Turkey molecular profiling in advanced cancers trial (TUMPACT). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1314] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
2
|
Üskent N, Ayla S, Mandel NM, Ozkan M, Teomete M, Baloglu H, Aydıncer C, Yergok H, Dogan E, Berk B, Yazar A. Prognostic significance of tumour tissue NeuGcGM3 ganglioside expression and predictive value of circulating tumour cell count monitoring in patients receiving racotumomab immunotherapy. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
3
|
Dane F, Akif Ozturk M, Gumus M, Guven A, Aliustaoglu M, Cabuk D, Teomete M, Basaran G, Fulden Yumuk P, Serdar Turhal N. Efficacy, safety and prognostic features of resected colon carcinoma treated in "real world" practice: a retrospective cohort-study. J BUON 2011; 16:257-264. [PMID: 21766495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
PURPOSE Treatment outcomes and prognostic features of a specific cancer generally come from prospective randomized studies. It seems reasonable to ask the question whether the results of prospective randomized studies entirely reflect the results of the population treated in "real world" practice. Therefore we performed a retrospective cohort analysis in order to find out the efficacy of adjuvant chemotherapy as well as the prognostic factors of our patient population treated in daily practice, and compared these findings with those defined in the prospective studies. METHODS Data of patients with high risk stage II and all stage III colon cancers treated with adjuvant chemotherapy were retrospectively analyzed. RESULTS A total of 190 patients were retrospectively analyzed. The rates of T2, T3, and T4 tumors were 4.2, 77.9, and 17.9%, respectively. Over 35% of the patients had stage II disease. Of the 5- fluorouracil (5-FU)-based chemotherapy group (n=141), 15% had a dose reduction because of toxicity and 73% were given the total planned dose and cycles, whereas these rates were 18.5 and 66% for oxaliplatin+5-FU treated group, respectively (p=0.66 and 0.44, respectively). The 3-year disease-free survival (DFS) and 5-year cancer-specific overall survival (OS) for all patients were 69.4 and 73%, respectively. In multivariate analysis, cancer-specific OS showed significant correlation with T stage (p=0.015) and with perineural invasion (p=0.024). Also patients ≥ 65 years old had significantly lower OS (p= 0.003) CONCLUSION This study is the fi rst to report the efficacy of adjuvant treatment in a curatively resected Turkish colon carcinoma population treated in "real world" practice. Our study showed that the treatment results and the prognostic parameters of Turkish colon carcinoma patients treated in "real world" practice are not different from those of selected patients treated in randomized prospective studies.
Collapse
Affiliation(s)
- F Dane
- Marmara University School of Medicine, Division of Medical Oncology, Istanbul, Turkey.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Turhal NS, Atalay Basaran G, Yurt N, Yurtseven G, Cabuk D, Teomete M, Gumus M. Weight gain after adjuvant chemotherapy in early breast cancer patients in Istanbul. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e11099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
5
|
Kefeli U, Yumuk PF, Ceyhan B, Dane F, Eroglu B, Cabuk D, Basaran G, Teomete M, Turhal NS. Pulmonary toxicity in patients receiving docetaxel chemotherapy. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e13532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e13532 Background: Docetaxel is used widely as monotherapy or in combination for the treatment of various types of cancers. Although rarely observed, pulmonary toxicity can be seen with docetaxel. This side effect had been reported mostly in non-small cell lung cancer patients receiving docetaxel. We aimed to investigate the pulmonary toxicity in patients receiving docetaxel chemotherapy other than lung cancer. Methods: 34 patients were investigated prospectively to demonstrate the pulmonary toxicity of docetaxel. Pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT) scans were applied to all patients before chemotherapy and 14 - 21 days after completion of treatment. We used a HRCT scoring system that was based on the previous studies. All HRCT images were reviewed by two different observers. Results: We have seen no pulmonary symptoms that may reflect pulmonary toxicity in 34 patients. There were statistically significant differences between pre- and post-treatment values of FEV1 (L/sec) (p<0.05), FEV1/FVC (%) (p<0.05), FEF25–75 (L/sec) (p<0.01), FEF25–75 (%) (p<0,01), DLCO (mL/mmHg/min) (p<0.001), DLCO (%) (p<0.001), DLCO/VA (DLCO/L) (p<0.05), and DLCO/VA (%) (p<0.05). Also, there was a statistically significant difference between the pre- and post-treatment HRCT scores. The differences between pre- and post- treatment values of pulmonary function tests were not correlated with the number of docetaxel cycles and cumulative dose. There was a statistical relationship between number of docetaxel cycles (r =0.468, p<0.0001), docetaxel cumulative dose (r=0,596, p<0.0001) and HRCT scores after completion of docetaxel treatment. Conclusions: Although we have shown that docetaxel treatment causes a decline in PFTs and worsens HRCT scores, the symptoms of patients were not consistent with these differences. Therefore, it should be noted that the negative effects of docetaxel on PFTs and HRCT scores should be investigated by increasing the number of patients. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- U. Kefeli
- Marmara University School of Medicine, Istanbul, Turkey; Marmara University School of Medicine, Istanbul, Turkey; Kadikoy Sonomed Medical Imaging Center, Istanbul, Turkey
| | - P. F. Yumuk
- Marmara University School of Medicine, Istanbul, Turkey; Marmara University School of Medicine, Istanbul, Turkey; Kadikoy Sonomed Medical Imaging Center, Istanbul, Turkey
| | - B. Ceyhan
- Marmara University School of Medicine, Istanbul, Turkey; Marmara University School of Medicine, Istanbul, Turkey; Kadikoy Sonomed Medical Imaging Center, Istanbul, Turkey
| | - F. Dane
- Marmara University School of Medicine, Istanbul, Turkey; Marmara University School of Medicine, Istanbul, Turkey; Kadikoy Sonomed Medical Imaging Center, Istanbul, Turkey
| | - B. Eroglu
- Marmara University School of Medicine, Istanbul, Turkey; Marmara University School of Medicine, Istanbul, Turkey; Kadikoy Sonomed Medical Imaging Center, Istanbul, Turkey
| | - D. Cabuk
- Marmara University School of Medicine, Istanbul, Turkey; Marmara University School of Medicine, Istanbul, Turkey; Kadikoy Sonomed Medical Imaging Center, Istanbul, Turkey
| | - G. Basaran
- Marmara University School of Medicine, Istanbul, Turkey; Marmara University School of Medicine, Istanbul, Turkey; Kadikoy Sonomed Medical Imaging Center, Istanbul, Turkey
| | - M. Teomete
- Marmara University School of Medicine, Istanbul, Turkey; Marmara University School of Medicine, Istanbul, Turkey; Kadikoy Sonomed Medical Imaging Center, Istanbul, Turkey
| | - N. S. Turhal
- Marmara University School of Medicine, Istanbul, Turkey; Marmara University School of Medicine, Istanbul, Turkey; Kadikoy Sonomed Medical Imaging Center, Istanbul, Turkey
| |
Collapse
|
6
|
Yumuk PF, Teomete M, Dane F, Cabuk D, Basaran G, Turhal NS. Impact of dose reductions of platinum compounds on survival in stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e19055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19055 Background: Platinum compounds are the main component of the CT in NSCLC. Standard recommended doses of cisplatin/carboplatin is usually couldn’t be administered and dose reductions are necessary because of side effects. We aimed to determine the effect of dose reductions of platinums on outcome of stage IIIB/IV NSCLC. Methods: Data of 420 patients were retrospectively reviewed. A platinum analogue was used in combination with vinorelbine, gemcitabine, paclitaxel, docetaxel or etoposide as first line treatment in 85% patients. Cumulative platinum doses and dose reduction ratios compared to standard doses were calculated. Patients with decreased GFR were excluded from the analysis. Results: Median age was 60 years (range: 28-87), 79% of patients were male, 31% were 65 yearsold/older, 55% had PS of 0, and 27% had stage IIIB disease. Histological subtypes were squamous cell in 32%, adenocarcinoma in 34%, and NSCLC in 31%. Median dose of cisplatin used per cycle was 67mg/m2 and carboplatin was 287mg/m2. 51% of the patients received standard or less than 10% reducted doses of platinum, while dose reductions were 10–20% in 19%, 21–30% in 24% of patients, and more than 31% in 6%. Median overall survival (OS) was 11 months, 1- year and 2-year OS ratios were 56% and 25%, respectively. Median time to progression was 5 months; 1-year progression free survival ratio was 18%. Gender, age, histologic subtype, and treatment with lower dose of platinum didn’t have any statistically significant impact on survival in univariate analysis. Patients with PS of 0, no weight loss, stage IIIB disease, receiving combination CT with docetaxel-cisplatin, and having partial response to treatment lived significantly longer. On multivariate analysis weight loss, stage and type of response to treatment had an impact on OS. Conclusions: Using lower doses of platinum compounds in combination chemotherapy for stage IIIB/IV non-small cell lung cancer might not have a negative impact on survival and definitely have a better toxicity profile. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. F. Yumuk
- Marmara University Medical School Hospital, Istanbul, Turkey
| | - M. Teomete
- Marmara University Medical School Hospital, Istanbul, Turkey
| | - F. Dane
- Marmara University Medical School Hospital, Istanbul, Turkey
| | - D. Cabuk
- Marmara University Medical School Hospital, Istanbul, Turkey
| | - G. Basaran
- Marmara University Medical School Hospital, Istanbul, Turkey
| | - N. S. Turhal
- Marmara University Medical School Hospital, Istanbul, Turkey
| |
Collapse
|
7
|
Turhal NS, Yurt N, Yurtseven G, Cabuk D, Teomete M, Gumus M. Weight gain after adjuvant treatment in breast cancer patients in Istanbul, Turkey. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e11620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e11620 Background: Weight gain is a common and unwanted result of chemotherapy. We wanted to find out how much weight Turkish beast cancer patients gains after chemotherapy and whether it lasts afterwards. Methods: 183 breast cancer patients who underwent a curative resection and received adjuvant chemotherapy afterwards in a private clinic between 1998 and 2007 are studied. Their weight before and after chemotherapy as well as their weight more than a year after chemotherapy is recorded together with their educational level, menopausal status, the type of chemotherapy or hormonal treatment, stage of disease, marital status, occupation and the underlying diseases. Results: Median age of patients is 53 and 72% is in menopause. Educational level is equally distributed for primary education (26%), High school (30%) and University and above (32%). Majority is (76%) married with two children (43%) and house wife (50%). Family history of any cancer is high (33%). Most of the patients had stage II cancer (57%), received anthracycline± taxane based chemotherapy (97%) and has no underlying disease (67%). The majority also does not smoke (72%) or drink alcohol (93%). Mean weight before the chemotherapy was 69.1 and increased to 70.8 upon completion of chemotherapy (p= 0.000) and 72 kg. more than a year after completion of chemotherapy (p=0.000). The other parameters including hormonal treatment, menopause, educational level and smoking do not have any effect on this weight increase. The all groups had similar weight gain with chemotherapy. Conclusions: Although upon starting the study we expected more, we confirmed some amount of weight gain with chemotherapy in Turkish patients and that gain is seen all across various social groups. The doctors should inform their patients of this change and precaution them toward this unwanted consequence. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- N. S. Turhal
- Marmara University Hospital, Istanbul, Turkey; Kartal Research & Education Hospital, Istanbul, Turkey
| | - N. Yurt
- Marmara University Hospital, Istanbul, Turkey; Kartal Research & Education Hospital, Istanbul, Turkey
| | - G. Yurtseven
- Marmara University Hospital, Istanbul, Turkey; Kartal Research & Education Hospital, Istanbul, Turkey
| | - D. Cabuk
- Marmara University Hospital, Istanbul, Turkey; Kartal Research & Education Hospital, Istanbul, Turkey
| | - M. Teomete
- Marmara University Hospital, Istanbul, Turkey; Kartal Research & Education Hospital, Istanbul, Turkey
| | - M. Gumus
- Marmara University Hospital, Istanbul, Turkey; Kartal Research & Education Hospital, Istanbul, Turkey
| |
Collapse
|
8
|
Dane F, Ozturk MA, Tecimer T, Atasoy BM, Cabuk D, Yumuk PF, Basaran G, Teomete M, Turhal NS. A case of Kikuchi-Fujimoto disease misdiagnosed as Hodgkin's lymphoma: the importance of second opinion. J BUON 2009; 14:309-311. [PMID: 19650184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Kikuchi-Fujimoto disease (KFD), a rare clinicopathological entity, is a benign and self-limiting disease. It was first described in 1972 by Kikuchi and Fujimoto in Japan independently. KFD is prevalent in Asia, although it may be seen in wide geographical areas, including Turkey. It mainly affects young women. Cervical lymphadenopathy is the most prominent sign and should be differentiated from lymphoproliferative, autoimmune, and infectious diseases. We report on a 30-year-old female patient who was referred to our medical oncology unit for chemotherapy and/or radiotherapy with diagnosis of Hodgkin's lymphoma. Ultimately her diagnosis was corrected as KFD after second opinion of the pathology specimens. We herein provide a brief review about KFD and the importance of second opinion of the pathology specimens.
Collapse
Affiliation(s)
- F Dane
- Division of Medical Oncology, Department of Pathology, Marmara University School Medicine, Istanbul, Turkey.
| | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Dane F, Gumus M, Ozturk MA, Cabuk D, Atasoy MB, Yumuk PF, Basaran G, Iyikesici MS, Teomete M, Abacioglu U, Turhal NS. Clinical features and outcome of adjuvant chemoradiotherapy in Turkish rectal carcinoma patients: Single institution experience. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Basaran GA, Cabuk D, Teomete M, Gulluoglu B, Kaya H, Dane F, Yumuk PF, Turhal NS. Benefit from adjuvant anthracyclines according to hormone receptor status. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.11513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Cabuk D, Basaran G, Kaya H, Gulluoglu B, Teomete M, Dane F, Yumuk PF, Turhal NS. Clinical outcome of triple-negative (TN) breast cancer (BC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.11526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Atalay Basaran G, Cabuk D, Dane F, Teomete M, Iyikesici S, Meltem E, Gulluoglu B, Kaya H, Abacıoglu U, Yumuk F, Turhal S. Clinical outcome of node-negative (NN) breast cancer (BC) patients. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.11102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11102 Background: Breast cancer patients (pts) with NN disease have diverse clinical outcomes. An optimal treatment decision- making tool has not been defined for this heterogeneous group. Methods: We identified pts with NN disease who have been treated between 1998–2006 in our department. We recorded the clinical/pathological, treatment characteristics and analyzed their survival outcome. High risk (HR) was defined as having at least one of the following features: age<35 yr-old, pts with grade 3 tumors (tms), ER and PR negative tms, tm size >2 cm. Results: Out of 597 early BC pts, 275 pts with NN disease were identified, 190 pts with HR, 85 with low risk (LR) features.The median age was 51 (26–83). The median follow up was 40 months (4–120 months). 47% pts were premenopausal. 31% pts had breast conserving surgery (BCS).58/29% pts had grade 2/3 tms. 34% pts with BCS or T3 tms received adjuvant radiotherapy. All receptor positive pts received adjuvant endocrine therapy (ET). In the HRNN group, 5% pts had tms>5cm, 51/40% pts had grade 2/3 tms, 43% pts had ER/PR negative tms. In the LRNN group 25/74% pts had grade 1/2 tms, no pt had receptor negative tm. 86%/51% pts received adjuvant chemotherapy (CT) in the HR and LRNN groups. 12%/48% pts received adjuvant ET alone in the HR and LRNN groups. 5pt in the HR and 1 pt in the LR group received no adjuvant systemic therapy due to their comorbidities and/or negative receptor status. So far, 14 pts had relapsed (8 from the HR, 6 from the LR group) and 3 pts died due to BC (1 from the HR, 2 from LR group). The 5-yr DFS was %94 in the HR and was %90 in the LR groups. HRNN pts had %98 and LRNN pts had %95 5-yr OS. Conclusion: It seems that prognostic information based merely on clinical/pathological characteristics might not accurately quantify the risk of recurrence and death, so that the decisions about adjuvant chemotherapy in NN breast cancer patients. Prospective evaluation of the performance of the new genomic prognostic tools compared to traditional prognostic factors is needed in order to more clearly define the HR vs LR subsets of NNBC pts. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - D. Cabuk
- Marmara University Hospital, Istanbul, Turkey
| | - F. Dane
- Marmara University Hospital, Istanbul, Turkey
| | - M. Teomete
- Marmara University Hospital, Istanbul, Turkey
| | | | - E. Meltem
- Marmara University Hospital, Istanbul, Turkey
| | | | - H. Kaya
- Marmara University Hospital, Istanbul, Turkey
| | | | - F. Yumuk
- Marmara University Hospital, Istanbul, Turkey
| | - S. Turhal
- Marmara University Hospital, Istanbul, Turkey
| |
Collapse
|
13
|
Dane F, Gumus M, Ozturk A, Yumuk F, Iyikesici S, Basaran G, Cabuk D, Teomete M, Turhal NS. Outcome of metastatic colorectal cancer patients receiving second line chemotherapy in Marmara University Hospital. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14588 Background: With the development of oxaliplatin and irinotecan, multiple effective regimens are now available in advanced colorectal cancer (CRC), both as first- and second-line treatment options. Exposure to all of the active drugs is effective in prolonging overall survival (OS) and time to progression (TTP). There are limited studies, if any, analyzing the outcome of second line chemotherapy in metastatic CRC in Turkey. Thus, we aimed to evaluate the outcome of second-line treatments in metastatic CRC patients. Methods: Among 173 patients with metastatic CRC who were given first line chemotherapy 106 (47 female, 59 male) were administered second line treatment after progression. All patients histologically confirmed colorectal adenocarcinoma with ECOG performance score of 2 or lower, and received second line therapy for metastatic CRC after experienced disease progression during or following treatment with first-line therapy were entered the study. The patients were evaluated clinically and radiologically after each three-cycle period, and chemotherapy was changed or stopped if the cancer has progressed. Age, gender, grade, chemotherapy type (combination vs single agent), lymphatic, vascular, and perineural invasion, were analyzed as prognostic factors. Results: At a median follow up of 10 (range 1–40) months from the start of second line chemotherapy median TTP and OS time were 5 and 16 months respectively. Median age was 62 years (range 27–89). After second line therapy 16% of the patient had objective response rate (0.9% complete responses plus 15.1% partial responses), 37.7% had stable disease resulting in a tumor control rate of 53.7%, and 46.2% had progressive disease. One-year progression free survival and OS rates were 15 % and 53.5%, respectively. No difference was seen in the survival of patients received combination or single agent second line chemotherapy (p=0.14). Overall, over 12% of the patients suffered from grade 3 or 4 adverse effects. In multivariate analysis histological grade (p=0.015) was the only independent prognostic factor for survival. Conclusion: The survival outcome and adverse effects of second line treatments in Turkish patients in our department with metastatic CRC is consistent with the worlds’ literature. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- F. Dane
- Marmara Univ Hosp, Istanbul, Turkey
| | - M. Gumus
- Marmara Univ Hosp, Istanbul, Turkey
| | | | - F. Yumuk
- Marmara Univ Hosp, Istanbul, Turkey
| | | | | | - D. Cabuk
- Marmara Univ Hosp, Istanbul, Turkey
| | | | | |
Collapse
|
14
|
Dane F, Gumus M, Iyikesici S, Yumuk F, Basaran G, Atasoy BM, Abacioglu U, Cabuk D, Teomete M, Turhal S. Outcome of rectal carcinoma patients receiving adjuvant chemoradiotherapy in Marmara University Hospital. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.13584] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
13584 Background: Surgical resection is the cornerstone of curative therapy for rectal cancer. Relapse rate following potentially curative resection is high in patients with stage II/III disease. Thus, chemoradiotherapy is the standard adjuvant treatment in resected stage II/III rectal carcinoma. There are limited studies, if any, analyzing the outcome of rectal cancer patients with stage II/III who received adjuvant chemoradiotherapy after curative resection in Turkey. Therefore, we aimed to analyze the treatment outcome, and the prognostic significance of various parameters in these patients. Methods: 106 patients with stage II/III rectal cancer treated with adjuvant chemoradiotherapy since 1997 until present were analyzed retrospectively. Patients received 5-fluorouracil (370–425mg/m2/day × 5days) and calcium leucovorin (20mg/m2/day × 5days), q4weeks, two courses before and two courses after radiotherapy. The 5-fluorouracil dose was reduced to, 225mg/m2/day given continuously as protracted short-term infusion during radiotherapy. 45–50.4 Gy radiotherapy was given to the pelvic region. Patients were followed-up every 3 months for the first 2 years and every 6 months thereafter. Age, gender, T stage, N stage, histological grade, lymphatic, vascular, and perineural invasion were analyzed as prognostic factors. Results: The median follow-up was 34 months. Median age was 59.5 years. Forty-four percent of the patients were node-negative. Lymphatic, vascular, and perineural invasion rate were 50.5%, 47.3%, and 32.3% respectively. Five-year disease-free and overall survival rates were 68.8% and 72.2%, respectively. Median survival time and median disease free-survival time were not reached at the time of analysis. In multivariate Cox regression analysis; T stage (p: 0.022), nodal stage (0.019), presence of lymphatic invasion (p: 0.0001), and the presence of vascular invasion (p:0.01) were independent prognostic factors. Conclusion: The adjuvant treatment outcome in Turkish patients in our department with stage II/III rectal cancer is similar to those reported in the Western studies. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- F. Dane
- Marmara University Hospital, Istanbul, Turkey
| | - M. Gumus
- Marmara University Hospital, Istanbul, Turkey
| | | | - F. Yumuk
- Marmara University Hospital, Istanbul, Turkey
| | - G. Basaran
- Marmara University Hospital, Istanbul, Turkey
| | | | | | - D. Cabuk
- Marmara University Hospital, Istanbul, Turkey
| | - M. Teomete
- Marmara University Hospital, Istanbul, Turkey
| | - S. Turhal
- Marmara University Hospital, Istanbul, Turkey
| |
Collapse
|